0550 GMT - Wuxi Biologics' near-to-medium term growth trajectory looks stable, CGS International analyst Lily Wang says in a note. The company has a resilient order backlog, which showed growth in 2024, signaling minimal disruption from U.S. geopolitical concerns, Wang says. CGSI raises its revenue forecasts by 7.2% and 10.6% for 2025 and 2026, respectively. It also lifts the target price to HK$25.06 from HK$10.87, to reflect more optimism around manufacturing projects. However, CGSI keeps a hold rating due to tariff uncertainty, as potentially higher costs from overseas facilities could pressure its gross profit margin. Clients may shift to rival manufacturers who are expanding their U.S. production capacity, adding risks to Wuxi Biologics' market share, Wang adds. Shares are 1.1% higher at HK$22.95. (kimberley.kao@wsj.com)
(END) Dow Jones Newswires
April 24, 2025 01:50 ET (05:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。